Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Aveo Pharmaceuticals Inc patents


Recent patent applications related to Aveo Pharmaceuticals Inc. Aveo Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Aveo Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Aveo Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Aveo Pharmaceuticals Inc-related inventors


Predicting tumor response to anti-erbb3 antibodies

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an erbb3 inhibitor, e.g, an anti-erbb3 antibody, is disclosed. The method is based on measurement of nrg1 expression at the rna level, or at the protein level, in a tissue sample from the tumor.. ... Aveo Pharmaceuticals Inc

Anti-gdf15 antibodies

Monoclonal antibodies that bind and inhibit the activity of human gdf15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human gdf15.. ... Aveo Pharmaceuticals Inc

Anti-erbb3 antibodies

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member erbb3/her3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of erbb3/her3.. ... Aveo Pharmaceuticals Inc

Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent

Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one gdf 15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one gdf 15 modulator.. ... Aveo Pharmaceuticals Inc

Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits gdf15 activity.. ... Aveo Pharmaceuticals Inc

Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator

The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (chf), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, gdf 15 activity in the subject.. ... Aveo Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Aveo Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Aveo Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###